Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.
Hosted on MSN
The Smartest Growth Stock to Buy With $500 Right Now
Vertex Pharmaceuticals should fare better in a down market than most stocks. The big biotech innovator has tremendous growth prospects. The stock offers an attractive risk-reward proposition. 10 ...
Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising new drugs on the horizon. Vertex's price looks quite attractive, relative to ...
One of Vertex's pipeline disappointments was that VX-993 didn't meet the primary endpoint in a phase 2 study evaluating the NaV1.8 pain signal inhibitor in treating acute pain following bunionectomy ...
Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising new drugs on the horizon. Vertex's price looks quite attractive, relative to ...
Todrick Hall has spoken publicly about the online clamour around the West End production of Burlesque for the first time. Hall directs and choreographs the production, which earned solid write-ups ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback